MAIN CONTENT
What 80,302 medical records reveal
Researchers examined records from 80,302 adults with type 2 diabetes treated at 301 specialist clinics in Italy between 2004 and 2024. None had established cardiovascular disease when they began GLP-1 receptor agonist treatment. Investigators compared people who continued using these medicines with those who discontinued, applying statistical matching to reduce differences in characteristics between the groups.
After matching, the groups contained 28,713 participants each. The combined outcome occurred at a rate of 3.94 per 100 person-years among those who stopped therapy, compared with 1.96 among persistent users. Put simply, that translates roughly into four versus two events annually for every 100 comparable people observed. The outcome also includes deaths from any cause, so the figures cannot be interpreted as the individual risk of having a stroke or heart attack.
Why association is not the same as cause
The research was retrospective and observational, rather than a trial randomly assigning patients to continue or stop treatment. People may discontinue because they cannot afford prescriptions, experience adverse effects, become seriously ill or encounter other barriers.














